Bottom line
- Before endoscopy, high-dose IV PPI may be considered (ESGE 2026) but must not delay endoscopy; likely reduces endoscopic treatment at index endoscopy; no proven effect on mortality, rebleeding or surgery.
- High-risk stigmata after endoscopic hemostasis: IV pantoprazole or esomeprazole 80 mg bolus, then 8 mg/h for 72 hours from endoscopy; then oral twice daily through day 14, then once daily.
- ESGE 2021 alternatives that can be considered: twice-daily high-dose IV bolus or oral PPI. Equivalence to the infusion is not established; best intermittent dose unknown.
- Low-risk stigmata (clean base, flat pigmented spot): no high-dose or IV PPI; do not continue a pre-endoscopy infusion for 72 hours; once-daily oral PPI.
One-Pager Handout (PDF)
Download the branded one-pager (PDF)Educational summary for pharmacists. Not a substitute for clinical judgment or institutional protocol.
Introduction
- Suspected variceal bleeding: follow your institution's variceal protocol.
- Assess hemodynamics and resuscitate first. Transfusion threshold without cardiovascular disease: ACG 2021 suggests 7 g/dL for hospitalized patients; ESGE 2021 recommends 7 g/dL or less if stable; ICON 2019 suggests below 8 g/dL. With cardiovascular disease: ICON 2019 suggests higher (no specific cutoff); ESGE 2021 recommends 8 g/dL or less if stable, post-transfusion target 10 g/dL or more.
- Before endoscopy, Glasgow-Blatchford 0 to 1: very low risk; may be discharged with outpatient follow-up (ICON 2019: no recommendation for or against pre-endoscopy Rockall here). Endoscopy within 24 hours of presentation is suggested (ACG 2021); emergent (6 h or less) or urgent (12 h or less) is not recommended unless hemodynamically unstable despite adequate resuscitation (ESGE 2026).
- Erythromycin before endoscopy is suggested (ACG 2021). ESGE 2021 recommends it in selected patients with severe or ongoing active bleeding; most common dose 250 mg IV by infusion, 30 to 120 min before endoscopy; contraindicated with macrolide sensitivity or prolonged QT.
PPI pharmacology
Swipe sideways to see all columns.
| Parameter | Pantoprazole | Esomeprazole | Omeprazole |
|---|---|---|---|
| Before endoscopy (optional; must not delay or replace endoscopy) | Tested: 80 mg IV bolus, then 8 mg/h (Rattanasupar 2016) | No regimen in these trials | Tested: 80 mg IV bolus, then 8 mg/h until endoscopy (Lau 2007) |
| After hemostasis of high-risk stigmata (spurting, oozing, nonbleeding visible vessel) or adherent clot not treated endoscopically (ESGE 2021 recommends): 72 h from endoscopy. Renal adjustment: none stated in the labels | Continuous: 80 mg IV bolus, then 8 mg/h. Intermittent: 80 mg IV once, then 40 mg IV every 12 h (trial regimen; not shown to be high dose). Not labelled for UGIB: safety and effectiveness not established | Continuous (labelled): 80 mg IV over 30 min, then 8 mg/h (Child-Pugh A or B: 6 mg/h; C: 4 mg/h) for 71.5 h, then oral (IV alone is not full treatment). Intermittent: none in the trials reviewed | IV not available in the U.S. Oral option: 40 mg PO twice daily for 72 h (trial regimen; not shown equivalent to the infusion) |
| Maintenance (oral). High-risk: twice daily through day 14 after endoscopy, then once daily (ICON 2019; ACG 2021); no strength in the sources reviewed. Low-risk: once daily at the label dose | Low-risk: oral label has no indication for healing an active ulcer. Hepatic (Child-Pugh A to C, oral data): exposure no higher than in CYP2C19 poor metabolizers, who need no adjustment; oral above 40 mg/day not studied | High-risk: 40 mg twice daily, days 3 to 14, in the trial behind ICON 2019 (Rockall 6 or more). Low-risk: as pantoprazole. Child-Pugh C: oral maximum 20 mg daily (erosive esophagitis healing) | Low-risk: no strength or duration for low-risk stigmata in the sources reviewed; active-ulcer label doses: 20 mg daily for 4 weeks, duodenal (some need 4 more); 40 mg daily for 4 to 8 weeks, benign gastric. Hepatic: exposure substantially increased; 10 mg daily (erosive esophagitis maintenance) |
| Administration | IV push over at least 2 min. PO: swallow whole, with or without food; do not split, chew or crush | IV push over at least 3 min (20 or 40 mg). PO: at least 1 h before meals; capsule whole or opened onto applesauce. NG: granules in 50 mL water, 60 mL catheter-tip syringe | PO: swallow whole 30 to 60 min before food |
| Adverse effects and warnings (all PPIs may raise C. difficile diarrhea risk, especially in hospitalized patients) | Headache, nausea, abdominal pain, diarrhea, vomiting; IV site thrombophlebitis. Warnings: acute tubulointerstitial nephritis; fractures (high-dose and long-term); severe skin reactions; cutaneous and systemic lupus; hypomagnesemia (rare; after 3 months or more, most often after a year); fundic gland polyps (long-term) | Headache, flatulence, nausea, dyspepsia, diarrhea; IV site reactions. Warnings: see label | Headache, abdominal pain, nausea, diarrhea, flatulence. Warnings: see label |
| Drug interactions (all three: rilpivirine-containing products contraindicated; avoid nelfinavir; avoid rifampin and St. John's wort (pantoprazole: these two are not in the label); warfarin: monitor INR, PT) | Atazanavir: see its label. High-dose methotrexate: consider temporary PPI withdrawal. Clopidogrel: no adjustment at approved IV doses; bleeding-infusion interaction not established | Avoid clopidogrel (consider another antiplatelet). Atazanavir: see its label. High-dose methotrexate: consider temporary PPI withdrawal | Avoid: atazanavir, clopidogrel |
| Compatibility | Reconstitute with NS; dilute with D5W or NS. Y-site: midazolam incompatible. May be incompatible with zinc-containing products. Flush the line before and after with D5W or NS. Contains edetate: consider zinc supplementation if prone to zinc deficiency | Reconstitute and dilute with NS, LR or D5W; give within 12 h (NS, LR) or 6 h (D5W). Bleeding regimen: dilute in 100 mL NS, give within 12 h. No other drugs through the same IV site or tubing | N/A |
| Monitoring | Rebleeding, most closely during the 72 hours. If recurrent, repeat endoscopy (ACG 2021 suggests; ESGE 2021 recommends, with hemostasis if indicated). Hemoglobin. Check IV site. Prolonged therapy, digoxin or diuretics: consider checking magnesium before and periodically | As pantoprazole | As pantoprazole |
Sources: references 1, 2, 19 to 23.
Key evidence
Swipe sideways to see all columns.
| Author, year | Design (n) | Intervention | Key findings |
|---|---|---|---|
| Muñoz-Carrillo, 2026 | Meta-analysis (12 RCTs, n=1,726) | Continuous vs intermittent IV bolus after hemostasis | Continuous not superior for rebleeding (RR 0.93, 95% CI 0.65 to 1.35; 11 trials, n=1,621; very low certainty); surgery and mortality: low certainty. Neither equivalence nor noninferiority established |
| Sriyudthsak, 2026 | RCT, multicenter, single-blind (n=124) | Omeprazole 40 mg PO twice daily vs pantoprazole 8 mg/h IV, 72 h after hemostasis | 72-h rebleeding 1.6% vs 4.8% (risk difference -3.1%, 95% CI -11.6% to 4.6%). Small; CI allows more rebleeding with oral |
| Kanno, 2022 | Meta-analysis (6 RCTs, n=2,223) | PPI (oral or IV) vs placebo, H2RA or no treatment, before endoscopy | Likely reduces endoscopic treatment at index endoscopy (OR 0.68, 95% CI 0.50 to 0.93; moderate certainty). No clear effect on mortality, rebleeding, surgery or high-risk stigmata (low certainty) |
| Sachar, 2014 | Meta-analysis (13 RCTs) | Intermittent IV or PO (40 mg IV daily to every 6 h) vs 80 mg IV, then 8 mg/h, 72 h, after endoscopic therapy | Intermittent noninferior for 7-day rebleeding (RR 0.72; upper 1-sided 95% bound 0.97); no outcome worse with intermittent |
| Chen, 2012 | RCT (n=201) | Pantoprazole 80 mg IV, then 8 mg/h, vs standard dose 40 mg IV once daily, 72 h | 30-day rebleeding 6.2% vs 5.2% (P=0.77) |
| Sung, 2009 | RCT, multicenter (n=764) | Esomeprazole 80 mg IV, then 8 mg/h, 72 h, vs placebo after hemostasis | 72-h rebleeding 5.9% vs 10.3% (P=0.026), sustained at 7 and 30 days. Surgery and mortality lower but not significant |
| Lau, 2007 | RCT, double-blind (n=638) | Omeprazole 80 mg IV, then 8 mg/h, vs placebo before next-morning endoscopy | Less endoscopic treatment: 19.1% vs 28.4% (P=0.007). No difference in rebleeding, surgery or 30-day mortality |
| Lau, 2000 | RCT, double-blind (n=240) | Omeprazole 80 mg IV, then 8 mg/h, 72 h, vs placebo after hemostasis of actively bleeding ulcers or nonbleeding visible vessels | 30-day rebleeding 6.7% vs 22.5% (HR 3.9 for placebo vs omeprazole, 95% CI 1.7 to 9.0). Most rebleeds during the 72-h infusion |
Clinical conclusions
After hemostasis of high-risk stigmata, high-dose PPI reduces rebleeding versus placebo (Lau 2000; Sung 2009). Versus standard dose, trials found no difference (Andriulli 2008; Chen 2012); ICON 2019 did not consider them equivalent.
Intermittent dosing met noninferiority for 7-day rebleeding (Sachar 2014), but Muñoz-Carrillo 2026 established neither equivalence nor noninferiority; ACG 2021 accepts either, ICON 2019 recommends the infusion.
Oral: not shown equivalent to infusion (Sriyudthsak 2026). Vonoprazan: ESGE 2026 lacks consensus on routine post-hemostasis use; AGA 2024: insufficient evidence for first-line use in high-risk bleeding ulcers.
Duration depends on cause; idiopathic ulcers need long-term anti-ulcer therapy (Laine 2012). H. pylori: test at index endoscopy; re-test if negative; treat if positive; document cure; then anti-ulcer therapy generally stops.
Stop NSAIDs (if one must resume: low-dose COX-2 selective NSAID plus PPI). After the twice-daily phase, reassess need; when continued therapy is not needed, lowest dose and shortest duration appropriate.
Prior ulcer bleeding on cardiovascular antiplatelets: continue PPI as long as antiplatelets continue (ICON 2019); ESGE 2021 recommends co-therapy with DAPT. Anticoagulation: ICON 2019 suggests PPI after ulcer bleeding; ESGE 2021 recommends it only with other gastrotoxic drugs such as NSAIDs or aspirin.
Follow your institution's protocol and formulary.
Educational summary for pharmacists. Not a substitute for clinical judgment or institutional protocol.
References
- Clinical Pharmacology [electronic version]. Elsevier, Tampa, FL. Retrieved February 17, 2021.
- UpToDate [electronic version]. Retrieved February 15, 2021.
- Andriulli A, et al. High- versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: a multicentre, randomized study. Am J Gastroenterol. 2008;103(12):3011-3018. PMID: 19086953.
- Sung JJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2009;150(7):455-464. PMID: 19221370.
- Kanno T, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2022;1(1):CD005415. doi:10.1002/14651858.CD005415.pub4. PMID: 34995368.
- Chen CC, et al. Randomised clinical trial: high-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers. Aliment Pharmacol Ther. 2012;35(8):894-903. PMID: 22369682.
- Sachar H, et al. Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis. JAMA Intern Med. 2014;174(11):1755-1762. PMID: 25201154.
- Rattanasupar A, Sengmanee S. Comparison of high dose and standard dose proton pump inhibitor before endoscopy in patients with non-portal hypertension bleeding. J Med Assoc Thai. 2016;99(9):988-995. PMID: 29927201.
- Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000;343(5):310-316. PMID: 10922420.
- Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med. 2007;356(16):1631-1640. PMID: 17442905.
- Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group. Ann Intern Med. 2019;171(11):805-822. PMID: 31634917.
- Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding. Am J Gastroenterol. 2021;116(5):899-917. PMID: 33929377.
- Gralnek IM, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline, Update 2021. Endoscopy. 2021;53(3):300-332. doi:10.1055/a-1369-5274. PMID: 33567467.
- Gralnek IM, et al. Endoscopic diagnosis and management of peptic ulcer bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, Update 2026. Endoscopy. 2026;58(8):899-924. doi:10.1055/a-2863-8314. PMID: 42127996.
- Muñoz-Carrillo JL, et al. Continuous infusion versus intermittent bolus proton pump inhibitor therapy following endoscopic hemostasis for bleeding peptic ulcers: a systematic review and meta-analysis. J Clin Med. 2026;15(19):7743. doi:10.3390/jcm15197743. PMID: 42882202.
- Sriyudthsak K, et al. High-dose oral omeprazole versus continuous intravenous pantoprazole in patients with high-risk peptic ulcer bleeding: a single-blinded multicenter RCT. J Gastroenterol Hepatol. 2026;41(9):2656-2664. doi:10.1111/jgh.70566. PMID: 42438169.
- Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012;107(3):345-360. doi:10.1038/ajg.2011.480. PMID: 22310222.
- Patel A, et al. AGA clinical practice update on integrating potassium-competitive acid blockers into clinical practice: expert review. Gastroenterology. 2024;167(6):1228-1238. doi:10.1053/j.gastro.2024.06.038. PMID: 39269391.
- PROTONIX I.V. (pantoprazole sodium) for injection, prescribing information. Wyeth Pharmaceuticals LLC (Pfizer). DailyMed set id 51e4144a-489e-436c-609a-39305f8f56ba, version 60, effective 2025-12-22.
- PROTONIX (pantoprazole sodium) delayed-release tablets and delayed-release oral suspension, prescribing information. Wyeth Pharmaceuticals LLC. DailyMed set id 08098cb2-c048-4640-f387-6beec4a38936, version 48, effective 2026-05-18.
- Esomeprazole sodium for injection, prescribing information. Slate Run Pharmaceuticals, LLC. DailyMed set id 23395673-116d-4a8e-b0ce-59f9ca5b3daf, version 4, effective 2026-06-22.
- NEXIUM (esomeprazole magnesium) delayed-release capsules and delayed-release oral suspension, prescribing information. AstraZeneca Pharmaceuticals LP. DailyMed set id f4853677-1622-4037-688b-fdf533a11d96, version 74, effective 2025-12-19.
- PRILOSEC (omeprazole magnesium) for delayed-release oral suspension, prescribing information. Covis Pharma US, Inc. DailyMed set id b6761f84-53ac-4745-a8c8-1e5427d7e179, version 8, effective 2024-03-19.
Never Miss a Friday Pearl
Get Pharmacy Pearls in your inbox every Friday
Free weekly clinical pearls written for pharmacists. Practical, evidence-based, and built for bedside use.
Free forever. Unsubscribe anytime. No spam, ever.